I don’t think the new Tarceva approval will have a material effect on the price OSIP shareholders get in an eventual buyout. From a commercial standpoint, the NSCLC maintenance indication is marginal in the US and probably non-existent in the EU.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.